bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-24 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
== Miscellaneous analysers == Some tests and test categories are unique in their mechanism or scope, and require a separate analyser for only a few tests, or even for only one test. Other tests are esoteric in nature—they are performed less frequently than other tests, and are generally more expensive and time-consuming to perform. Even so, the current shortage of qualified clinical laboratory professionals has spurred manufacturers to develop automated systems for even these rarely performed tests. Analysers that fall into this category include instruments that perform:
As such, the yeasts involved in what has been typically called top-cropping or top-fermenting ale may be both Saccharomyces cerevisiae and complex hybrids of Saccharomyces cerevisiae and Saccharomyces kudriavzevii. Three notable ales, Chimay, Orval and Westmalle, are fermented with these hybrid strains, which are identical to wine yeasts from Switzerland.
Kiwis and shorebirds with long bills probe for invertebrates; shorebirds' varied bill lengths and feeding methods result in the separation of ecological niches. Divers, diving ducks, penguins and auks pursue their prey underwater, using their wings or feet for propulsion, while aerial predators such as sulids, kingfishers and terns plunge dive after their prey. Flamingos, three species of prion, and some ducks are filter feeders. Geese and dabbling ducks are primarily grazers. Some species, including frigatebirds, gulls, and skuas, engage in kleptoparasitism, stealing food items from other birds. Kleptoparasitism is thought to be a supplement to food obtained by hunting, rather than a significant part of any species' diet; a study of great frigatebirds stealing from masked boobies estimated that the frigatebirds stole at most 40% of their food and on average stole only 5%. Other birds are scavengers; some of these, like vultures, are specialised carrion eaters, while others, like gulls, corvids, or other birds of prey, are opportunists.
=== United Arab Emirates === The United Arab Emirates has long been known as a hub of illicit financial flows and corruption. A large number business, real estate and financial transactions of the country majorly involve some sort of illegal activity. Moreover, several corrupt and criminal actors from across the world operate through or from the Emirates, including European money launderers, Nigerian kleptocrats, East African gold smugglers, Afghan warlords and others. Even the royal family members of the UAE are often known to be associated with certain cases of offshore holdings. However, in 2022, the UAE fell into a risk of being named in the Financial Action Task Force (FATF) "grey list". The list defines nations determined to have "strategic deficiencies" in combating money laundering and terrorist financing. On 4 March 2022, FATF placed the UAE in its 'grey' list of countries that are subject to increased monitoring. In April 2020, the Emirates had been warned of its money laundering activities, where FATF called the UAE's limited prosecutions on the issue a "concern". In November 2021, the group received a report from the Emirates, which did not reach much of the thresholds required for avoid the grey list. A report in June 2023 revealed that the Western countries, including Germany, Italy, Greece and the U.S., had been pushing FATF to remove the UAE from its grey list on money laundering, despite the Emirates’ image of being a haven for illicit flows.
Sources: en.wikipedia.org
=== The Black Box === Valve planned on releasing an additional compilation for Windows entitled The Black Box, which would have contained only the three new games released as a part of the Orange Box—Half-Life 2: Episode Two, Portal, and Team Fortress 2. The Black Box was later cancelled for retail and only made available through Steam exclusively to owners of certain ATI graphics cards, who received a voucher for a free copy of The Black Box. During development, the simultaneous release of two game compilation packages with different content combinations was touted by Valve as a new direction for the game industry. Gabe Newell, co-founder of Valve, said, "The Black Box and The Orange Box represent a new approach to publishing multiple products on multiple platforms." After first discontinuing The Black Box, however, Valve released all the new material for individual download via Steam. The Black Box was to be priced US$10 lower than The Orange Box which would have made it $39.95 on PC and $49.95 on console in the U.S. if it used The Orange Box launch price as a baseline. To compensate for the cancellation of The Black Box, Valve offered gift subscriptions to Steam users who had previously purchased Half-Life 2 or Half-Life 2: Episode One and then purchased The Orange Box so that they could give their second copies of those two games as gifts to people added to their Steam Friends list. Still, the cancellation of The Black Box sparked complaints from game critics and consumers alike, unhappy that they were obliged to pay for games that they already owned.
==== Trophic interactions ==== Assimilation of diet into tissue has a tissue-specific fractionation known as the trophic discrimination factor. Diet sources can be tracked through a food web via deuterium isotope profiles, though this is complicated by deuterium having two potential sources – water and food. Food more strongly impacts δD than does exchange with surrounding water, and that signal is seen across trophic levels. However, different organisms derive organic hydrogen in varying ratios of water to food: for example, in quail, 20-30% of organic hydrogen was from water and the remainder from food. The precise percentage of hydrogen from water, depended on tissue source and metabolic activity. In chironomids, 31-47% of biomass hydrogen derived from water, and in microbes as much as 100% of fatty acid hydrogen can be derived from water depending on substrate. In caterpillars, diet δD from organic matter correlates linearly with tissue δD. The same relationship does not appear to hold consistently for diet δD from water, however – water derived from either the caterpillar or its prey plant is more 2H-enriched than their organic material. Going up trophic levels from prey (plant) to predator (caterpillar) results in an isotopic enrichment. This same trend of enrichment is seen in many other animals - carnivores, omnivores, and herbivores - and seems to follow 15N relative abundances. Carnivores at the same trophic level tend to exhibit the same level of 2H enrichment.
== Distribution and habitat == The species is widespread in temperate forests of the Northern Hemisphere. In North America, it can be found from August to November. It is a white-rot wood-decay fungus on conifer wood, particularly hemlock (genus Tsuga).
Sources: en.wikipedia.org
==== Federal drug schedule system introduced ==== The Richard Nixon presidency (1969–74) incorporated his predecessor's anti-drug initiative in a tough-on-crime platform. In his 1968 presidential nomination acceptance speech, Nixon promised, "Our new Attorney General will ... launch a war against organized crime in this country. ... will be an active belligerent against the loan sharks and the numbers racketeers that rob the urban poor. ... will open a new front against the filth peddlers and the narcotics peddlers who are corrupting the lives of the children of this country." In a 1969 special message to Congress, he identified drug abuse as "a serious national threat". On October 27, 1970, Nixon signed into law the Comprehensive Drug Abuse Prevention and Control Act of 1970, establishing his approach to drug control. The act largely repealed mandatory minimum sentences: simple possession was reduced from a felony to a misdemeanor, the first offense carried a maximum of one year in prison, and judges had the latitude to assign probation, parole or dismissal. Penalties for trafficking were increased, up to life depending on the quantity and type of drug. Funding was authorized for the Department of Health, Education and Welfare to provide treatment, rehabilitation and education. Additional federal drug agents were provided, and a "no-knock" power was instituted, that allowed entry into homes without warning to prevent evidence from being destroyed. Licensing and stricter reporting and record-keeping for pharmaceutical manufacturers and distributors occurred under the act.
== Adverse effects == GLP-1 agonists' most common adverse effects are gastrointestinal. These limit the maximum tolerated dose and require gradual dose escalation. Nausea, vomiting, diarrhea, and constipation are commonly reported. Nausea is directly related to serum concentration and is reported in up to three-quarters of people using short-acting GLP-1 agonists, but fewer of those using long-acting agonists. Injection site reactions are common, especially with shorter-acting drugs. GLP-1 agonists appear to increase the risk of non-arteritic anterior ischemic optic neuropathy. Some people develop anti-drug antibodies, which are more common with exenatide (the antibodies were detectable in a third or more of people) than other GLP-1 agonists and can decrease efficacy. Gallstones may form while attempting to induce rapid weight loss. The risk of aspiration under anesthesia is higher due to delayed gastric emptying, according to case reports. In 2024, the American Society of Anesthesiologists and others suggested suspending GLP-1 agonist treatment in most people on the day of the procedure for daily dosing or a week before for weekly dosing. A 2024 study suggested that GLP-1 weight-loss medications do not increase the risk of suicide or suicidal thoughts in children and adolescents, contrary to some previous concerns. The study included over 54,000 U.S. adolescents and reported a 33% reduction in the risk of suicidal thoughts and attempts among those using the drugs compared to those who did not.
For amino acids with uncharged side-chains the zwitterion predominates at pH values between the two pKa values, but coexists in equilibrium with small amounts of net negative and net positive ions. At the midpoint between the two pKa values, the trace amount of net negative and trace of net positive ions balance, so that average net charge of all forms present is zero. This pH is known as the isoelectric point pI, so pI = 1/2(pKa1 + pKa2). For amino acids with charged side chains, the pKa of the side chain is involved. Thus for aspartate or glutamate with negative side chains, the terminal amino group is essentially entirely in the charged form −NH+3, but this positive charge needs to be balanced by the state with just one C-terminal carboxylate group is negatively charged. This occurs halfway between the two carboxylate pKa values: pI = 1/2(pKa1 + pKa(R)), where pKa(R) is the side chain pKa. Similar considerations apply to other amino acids with ionizable side-chains, including not only glutamate (similar to aspartate), but also cysteine, histidine, lysine, tyrosine and arginine with positive side chains. Amino acids have zero mobility in electrophoresis at their isoelectric point, although this behaviour is more usually exploited for peptides and proteins than single amino acids. Zwitterionic amino acids exhibit minimal solubility at their isoelectric point, and in some cases can be isolated from aqueous solution by adjusting the pH to the appropriate isoelectric value.
Difficulty staying awake Mental confusion Impaired motor functions Impaired reflexes Impaired coordination Impaired balance Dizziness Respiratory depression Low blood pressure Coma Death Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a four-year-old boy who overdosed on clonazepam. The combination of clonazepam and certain barbiturates (for example, amobarbital), at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression. Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.